The development of novel targeted therapies for cancer is a crucial priority in the field of oncology. This is particularly true for some types of leukemias that are characterized by a high risk of relapse and poor response to conventional therapies. For these diseases, it is imperative to identify and act on the essential signals that drive the malignant transformation and the survival of cancer cells.
